Vivos Therapeutics Inc Ordinary Shares VVOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
-
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
-
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
-
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
-
Vivos Therapeutics Shares More than Double on FDA's 510(k) Clearance for Sleep Apnea Treatment
Trading Information
- Previous Close Price
- $3.24
- Day Range
- $3.01–3.29
- 52-Week Range
- $1.91–48.79
- Bid/Ask
- $3.04 / $3.07
- Market Cap
- $10.41 Mil
- Volume/Avg
- 235,942 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 114
- Website
- https://www.vivos.com
Valuation
|
Metric
|
VVOS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.64 |
Price/Sales | 0.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VVOS
|
|---|---|
Quick Ratio | 1.10 |
Current Ratio | 1.18 |
Interest Coverage | — |
Quick Ratio
VVOS
Profitability
|
Metric
|
VVOS
|
|---|---|
Return on Assets (Normalized) | −100.17% |
Return on Equity (Normalized) | −658.98% |
Return on Invested Capital (Normalized) | −321.63% |
Return on Assets
VVOS
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Jyrzfjvt | Zjnfm | $196.1 Bil | |||
| Stryker Corp
SYK
| Ksjrqtqf | Bfkj | $137.7 Bil | |||
| Boston Scientific Corp
BSX
| Pjqbplxm | Xkmlbr | $122.3 Bil | |||
| Medtronic PLC
MDT
| Blcbpdfq | Xrthvxl | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Pvwvslmjby | Xxjxpq | $39.6 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Qgt | Rcqrt | $29.3 Bil | |||
| DexCom Inc
DXCM
| Skshgjrhr | Bzwd | $27.1 Bil | |||
| Steris PLC
STE
| Thnshvzjz | Bkgxvsv | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Fsnmrhtrsx | Hppz | $21.9 Bil | |||
| Insulet Corp
PODD
| Vbgtsmwdt | Xlbzb | $16.5 Bil |
United States